95.35 USD
↗ 3.78 (4.13%)AT CLOSE (11:59 AM EDT)
Dianthus Therapeutics, Inc. Common Stock
DNTHNASDAQ • USD
79.85
↘ 15.50 (16.30%)
POST MARKET (AS OF 07:53 PM EDT)
Post Market
AS OF 07:53 PM EDT
79.85
↘ 15.50 (16.30%)
Market: CLOSED
Dianthus Therapeutics, Inc. Common Stock (DNTH) trades at $95.35 per share. Technicals currently rate "Strong Buy" while our fundamental analysis reads "Neutral". Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 1/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.
Technical & fundamental data as of Jun 26, 2026.
Open?$91.80
High?$96.78
Low?$88.56
Prev. Close?$91.57
Volume?5.7M
Avg. Volume?1.2M
VWAP?$92.87
Rel. Volume?4.82x
Bid / Ask
Bid?$82.20 × 100
Ask?$112.86 × 100
Spread?$30.66
Midpoint?$97.53
Valuation & Ratios
Market Cap?5.2B
Shares Out?54.7M
Float?50.4M
Float %?92.6%
P/E Ratio?N/A
P/B Ratio?4.34
EPS?-$3.18
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
Employees
92
Market Cap
5.0B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2023-09-12
Address
7 TIMES SQUARE
NEW YORK, NY 10036
Phone: 929-999-4055
NEW YORK, NY 10036
Phone: 929-999-4055
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+3/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?▲ Bullish(+3/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?6
Z-Score?100
Momentum?23
Short Sent.?60
Piotroski F-Score?1/9Weak
Altman Z-Score?68.74Safe
Confidence?55%Low
Short InterestHigh
Short % of Float?13.84%High
Short Interest?7.0M
Days to Cover?5.7
Free Float50.4M
Avg Daily Volume1.2M
Settlement Date2026-06-15
Financial Health
Current Ratio?29.25Strong
Quick Ratio?29.25Strong
Cash Ratio?16.40Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score58/100
P/E?N/A▾
P/B?4.34FAIR▾
Peers100
S&P41
P/S?3,901.52HIGH▾
Peers100
S&P3
P/FCF?N/A▾
EV/EBITDA?-24.0CHEAP▾
S&P97
EV/Sales?3,431.71HIGH▾
Peers100
S&P3
Returns & Efficiency
ROE?-14.5%WEAK▾
S&P9
ROA?-13.9%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-130485000
Enterprise Value?$4.6B
Fundamentals ratios updated end of day